Loading stock data…
$1.94-0.05 (-2.52%)
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally.
Aytu BioPharma, Inc. in the Healthcare sector is trading at $1.94 with a market capitalization of $21M. Wall Street consensus targets $9.67 (3 analysts), implying a +398.3% move over the next 12 months. The stock is currently near its 52-week low of $1.80, remaining 17.8% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 12 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $12.41M↓ | $15.16M↑ | $13.89M↓ | $15.13M↓ | $18.45M |
| Gross Profit | $7.60M↓ | $9.62M↑ | $9.19M↓ | $10.25M↓ | $12.81M |
| Operating Income | -$4.06M↓ | -$1.97M↓ | -$1.50M↓ | $640,000↓ | $2.42M |
| Net Income | -$5.62M↑ | -$10.58M↓ | $1.97M↑ | -$19.82M↓ | $3.99M |
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), inc...